Ministry of Foreign Affairs of Japan Medical Visa Guarantee Agency No. B-66
Fukuoka Prefecture, Japan Travel service No. 35
Japanese Registration Support Organization No. 19-000303
Japan Medical Equipment Sales and Leasing
Medical Supporter
Accompanied with heart, medical care support in Japan
Immune checkpoint inhibitor Opdivo
HIROI CLINIC
About Opdivo
Opdivo, also known as an immune checkpoint inhibitor, can have an effect on non-small cell lung cancer that cannot be surgically removed or progresses and recurs. It is a new drug in recent years. Cancer treatment drugs include anticancer drugs, molecular target drugs, hormonal drugs, etc., but immune checkpoint inhibitors have a different mechanism of action from these drugs, so they have attracted attention, and countries around the world are actively developing such drugs.
immune checkpoint inhibitors
Immune cells themselves have the ability to attack and eliminate foreign substances in the body. In the early stages, when the number of cancer cells is low, immune cells are usually able to eliminate cancer cells. However, overactivation of immune cells can trigger an autoimmune response that attacks their own normal cells, so immune cells have molecules on their surface that suppress the immune response, called immune checkpoints, and some cancer cells have Molecules that act on immune checkpoints to prevent an immune response from occurring. The role of immune checkpoint inhibitors, therefore, is to block the function of these molecules, awakening the primordial ability of immune cells to attack cancer cells. Based on the results of multiple clinical trials, immune checkpoint inhibitors have been shown to be effective against a variety of cancers.
Helps facilitate the attack on cancer cells by releasing the immune suppression of T cells
When Opdivo enters the blood, it will connect with PD-1 on T cells, thereby blocking the combination with cancer cells and releasing the suppression of immune function. This action allows T cells to attack cancer cells without interference.
Side Effects Confirmed by Opdivo in Japan
-
Interstitial lung disease (pneumonia, lung infiltrates, lung injury, etc.)
-
Myasthenia gravis, myocarditis, myositis, rhabdomyolysis, or comorbidities of these conditions
-
Colitis, enteritis, severe diarrhea
-
type 1 diabetes
-
Severe blood disorders (immune thrombocytopenic purpura, hemolytic anemia, agranulocytosis, etc.)
-
Pulmonary insufficiency, liver dysfunction, hepatitis, sclerosing cholangitis
-
Thyroid dysfunction
-
pituitary dysfunction
-
nervous disorder
-
kidney dysfunction
-
adrenal dysfunction
-
encephalitis
-
severe skin disorder
-
venous thromboembolism
-
hemophagocytosis syndromegroup
-
tuberculosis
-
pancreatitis
For these side effects, corresponding management and treatment should be carried out according to the specific conditions of the patients. if inOpdivoAny discomfort or side effects during use should be reported to a doctor immediately for proper treatment and treatment.
Remarks: Taiwan has aboutOpdivoReferences for side effects
Symptoms of Opdivo Adaptation in Japan
-
malignant melanoma
-
Unresectable, progressive or recurrent non-small cell lung cancer
-
unresectable or metastatic renal cell carcinoma
-
relapsed or refractory classical Hodgkin lymphoma
-
recurrent or metastatic head and neck cancer
-
Progressive, recurrent gastric cancer that has worsened and is unresectable after chemotherapy
-
After chemotherapy, worsening andcan'tprogress of resection,recurrent pleural mesothelioma
-
After chemotherapy, worsening andcan'tprogress of resection,Recurrent colorectal cancer with MSI-High
-
After chemotherapy, worsening andcan'tprogress of resection,recurrent esophageal cancer
Remarks: Taiwan has about Opdivo References for Adaptive Symptoms
In some cases, the Hiroi Clinic will use a lower dose of Opdivo about 20mg, and the general dosage in Japan is 240mg. There are also some cases where the use of lower doses has shown effects and can suppress the occurrence of side effects. The clinic recommends adjusting according to each patient's situation and closely observing the efficacy.
In some cases, Guangjing Clinic uses a lower dose of Opdivo (20mg), while the general dose in Japan is 240mg. There are also cases where the lower dose has shown effects and can suppress the occurrence of side effects. The clinic recommends adjusting the dose according to the situation of each patient and closely observing the efficacy. Video information provided by Guangjing Clinic.
Opdivo plus Yervoy therapy
About Opdivo and Yervoy combination therapy is an approach that combines two different immune checkpoint inhibitors for treatment. They have the effect of relieving immunosuppression on T cells. Opdivo acts on "PD-1" on T cells, and Yervoy acts on "CTLA-4". Each of them binds to the antigen of T cells, blocks the inhibitory signal, and relieves immune suppression. This way, the T cells are able to attack the cancer cells again without interference. Opdivo and Yervoy combination therapy further enhances the attack power against cancer cells by combining two immune checkpoint inhibitors to achieve more effective treatment.
About Yervoy
Yervoy is a drug that binds CTLA-4, blocking its interaction with certain substances. It has been reported that when CTLA-4 is blocked, it can promote the activation and proliferation of T cells.
Yervoy adaptation symptoms
unresectable malignant melanoma
incurable or metastatic renal cell carcinoma
After chemotherapy,Unresectable colorectal cancer with MSI-High
Unresectable progressive, recurrent non-small cell lung cancer
Unresectable progressive,recurrent malignant pleural mesothelioma
Remarks: Taiwan has aboutYervoyReferences for Adaptive Symptoms
Clinic introduction
Comfortable and spacious clinic interior
Dean's introduction
Dr.
HIROI NOBUYUKI
1990 Graduated from Aichi Medical University
worked in
First Department of Surgery, Aichi Medical University Hospital
Second Surgery Department, Affiliated Hospital of Wakayama Prefectural Medical University
Department of Surgery, Osaka Minami Hospital
Medical corporation Yoshihidekai Takaishi Fujii Hospital general medical department director (Osaka), etc.
2015 Established Hiroi clinic
Director Hiroi has the experience of treating more than 150 terminal cancer patients, and has accumulated rich knowledge and experience in clinical practice. Use this knowledge and experience to provide effective methods for terminal cancer patients and help as many people as possible "beat cancer".
Clinic address
〒663-8113 22-22
Koshienguchi 4-chome, Nishinomiya City, Hyogo Prefecture
If you have any questions, please feel free to contact us through any of the methods below.
CONTACT US
TW contact only: ＋886-90-5563-717
JP For emergency contact: ＋81-80-4276-3930
JP Tel / Fax: ＋81-92 -984-3200
Mail: service@medicalsupporter.org
LINE@ ID: @medicalsupporter
LINE & WeChat & Skype: medicalsupporter
LINE@
LINE
